Understanding how ribosomes in a fungus respond to stress
Ribosome Heterogeneity in Cryptococcus neoformans
This study is looking at how a fungus that can make people with weakened immune systems sick adapts to stress in the body, with the goal of finding new ways to create better treatments for tough fungal infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-11193576 on NIH RePORTER |
What this research studies
This research investigates the ribosomes of the fungus Cryptococcus neoformans, which is known to cause serious infections in immunocompromised patients. The study aims to identify how these ribosomes adapt to stress conditions that occur in the human body, particularly during infections. By exploring specific proteins that interact with the ribosome, the research seeks to uncover new targets for antifungal therapies. This could lead to the development of more effective treatments for fungal infections that are resistant to current medications.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with weakened immune systems, such as those undergoing transplantation or living with HIV/AIDS, who are at risk for invasive fungal infections.
Not a fit: Patients with fungal infections that are not caused by Cryptococcus neoformans may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of novel antifungal therapies that are more effective against resistant fungal infections.
How similar studies have performed: Other research has shown promise in targeting ribosomal functions in fungi, suggesting that this approach could be a viable strategy for developing new antifungal treatments.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Panepinto, John C — State University of New York at Buffalo
- Study coordinator: Panepinto, John C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.